{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:33:16Z","timestamp":1787027596397,"version":"build-2736575974"},"reference-count":82,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Metallo-beta-lactamases-producing (MBL) Enterobacterales is a growing problem worldwide. The optimization of antibiotic therapy is challenging. The pivotal available therapeutic options are either the combination of ceftazidime\/avibactam and aztreonam or cefiderocol. Colistin, fosfomycin, tetracyclines and aminoglycosides are also frequently effective in vitro, but are associated with less bactericidal activity or more toxicity. Prior to the availability of antibiotic susceptibility testing, severe infections should be treated with a combination therapy. A careful optimization of the pharmacokinetic\/pharmacodynamic properties of antimicrobials is instrumental in severe infections. The rules of antibiotic therapy are also reported and discussed. To conclude, treatment of severe MBL infections in critically ill patients is difficult. It should be individualized with a close collaboration of intensivists with microbiologists, pharmacists and infection control practitioners.<\/jats:p>","DOI":"10.3390\/antibiotics11020144","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T20:44:33Z","timestamp":1643143473000},"page":"144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6063-7383","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"first","affiliation":[{"name":"APHP, Service de M\u00e9decine Intensive et R\u00e9animation Infectieuse, H\u00f4pital Bichat Claude-Bernard, 46 Rue Henri Huchard, 75018 Paris, France"},{"name":"IAME, INSERM, University of Paris, 75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Henri","family":"Wicky","sequence":"additional","affiliation":[{"name":"APHP, Service de M\u00e9decine Intensive et R\u00e9animation Infectieuse, H\u00f4pital Bichat Claude-Bernard, 46 Rue Henri Huchard, 75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6379-1928","authenticated-orcid":false,"given":"Etienne","family":"de Montmollin","sequence":"additional","affiliation":[{"name":"APHP, Service de M\u00e9decine Intensive et R\u00e9animation Infectieuse, H\u00f4pital Bichat Claude-Bernard, 46 Rue Henri Huchard, 75018 Paris, France"},{"name":"IAME, INSERM, University of Paris, 75018 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Polemis, M., Mandilara, G., Pappa, O., Argyropoulou, A., Perivolioti, E., Koudoumnakis, N., Pournaras, S., Vasilakopoulou, A., Vourli, S., and Katsifa, H. (2021). COVID-19 and Antimicrobial Resistance: Data from the Greek Electronic System for the Surveillance of Antimicrobial Resistance-WHONET-Greece (January 2018\u2013March 2021). Life, 11.","DOI":"10.3390\/life11100996"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e0200020","DOI":"10.1128\/AAC.02000-20","article-title":"Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017","volume":"65","author":"Kazmierczak","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115557","DOI":"10.1016\/j.diagmicrobio.2021.115557","article-title":"Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018\u20132020)","volume":"102","author":"Sader","year":"2022","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015\u20132017)","volume":"73","author":"Sader","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e4521","DOI":"10.1093\/cid\/ciaa1464","article-title":"Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000\u20132017","volume":"73","author":"Babiker","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_6","first-page":"1900123","article-title":"Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018","volume":"24","author":"Brolund","year":"2019","journal-title":"Euro Surveill. Bull. Eur. Mal. Transm. Eur. Commun. Dis. Bull."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e00047-19","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of beta-Lactamase-Producing Pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-019-11615-w","article-title":"Protein determinants of dissemination and host specificity of metallo-beta-lactamases","volume":"10","author":"Lopez","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_9","first-page":"228","article-title":"Risk factors for carbapenem-resistant Gram-negative bacterial infections: A systematic review","volume":"27","author":"Giannella","year":"2021","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1017\/S0950268819000256","article-title":"Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae","volume":"147","author":"Snyder","year":"2019","journal-title":"Epidemiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/AAC.00782-08","article-title":"Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections","volume":"53","author":"Daikos","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s10096-020-03845-4","article-title":"Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018","volume":"39","author":"Perovic","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-\u03b2-lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_14","first-page":"780","article-title":"Clinical Outcome of Patients on Ceftazidime-Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae","volume":"25","author":"Nagvekar","year":"2021","journal-title":"Indian J. Crit. Care Med. Peer-Rev. Off. Publ. Indian Soc. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00134-019-05520-5","article-title":"Rationalizing antimicrobial therapy in the ICU: A narrative review","volume":"45","author":"Timsit","year":"2019","journal-title":"Intensive Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/2229-516X.198520","article-title":"Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes","volume":"7","author":"Mariappan","year":"2017","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ajic.2015.12.005","article-title":"Risk of infection following colonization with carbapenem-resistant Enterobactericeae: A systematic review","volume":"44","author":"Tischendorf","year":"2016","journal-title":"Am. J. Infect. Control"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhin.2016.05.018","article-title":"Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: A retrospective matched cohort comparison with non-carriers","volume":"94","author":"Dickstein","year":"2016","journal-title":"J. Hosp. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lin, Q., Wang, Y., Yu, J., Li, S., Zhang, Y., Wang, H., Lai, X., Liu, D., Mao, L., and Luo, Y. (2021). Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06315-0"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12941-015-0088-y","article-title":"Simple bedside score to optimize the time and the decision to initiate appropriate therapy for carbapenem-resistant Enterobacteriaceae","volume":"14","author":"Leibman","year":"2015","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e00845-19","DOI":"10.1128\/AAC.00845-19","article-title":"Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae","volume":"63","author":"Marimuthu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/QCO.0000000000000713","article-title":"Molecular diagnostic methods for pneumonia: How can they be applied in practice?","volume":"34","author":"Kerneis","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Renaud, C., and Kollef, M.H. (2022). Classical and Molecular Techniques to Diagnose HAP\/VAP. Semin. Respir. Crit. Care Med.","DOI":"10.1055\/s-0041-1739359"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e0006321","DOI":"10.1128\/AAC.00063-21","article-title":"A Pragmatic Machine Learning Model To Predict Carbapenem Resistance","volume":"65","author":"Mcguire","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mauri, C., Maraolo, A.E., Di Bella, S., Luzzaro, F., and Principe, L. (2021). The Revival of Aztreonam in Combination with Avibactam against Metallo-beta-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics, 10.","DOI":"10.3390\/antibiotics10081012"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"105842","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: Report of two cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","article-title":"Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model","volume":"75","author":"Lodise","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jac\/dkz497","article-title":"Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: Results from the REJUVENATE study","volume":"75","author":"Cornely","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00966-20","DOI":"10.1128\/JCM.00966-20","article-title":"Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli","volume":"59","author":"Albano","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nurjadi, D., Kocer, K., Chanthalangsy, Q., Klein, S., Heeg, K., and Boutin, S. (2021). New Delhi metallo-beta-lactamase facilitates the emergence of cefiderocol resistance in Enterobacter cloacae. Antimicrob. Agents Chemother., AAC0201121.","DOI":"10.1128\/aac.02011-21"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Simner, P.J., Mostafa, H.H., Bergman, Y., Ante, M., Tekle, T., Adebayo, A., Beisken, S., Dzintars, K., and Tamma, P.D. (2021). Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy Is Associated with Increased blaNDM-5 Copy Number and Gene Expression. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., ciab888.","DOI":"10.1093\/cid\/ciab888"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Paul, M., Carrara, E., Retamar, P., T\u00e4ngd\u00e9n, T., Bitterman, R., Bonomo, R.A., de Waele, J., Daikos, G.L., Akova, M., and Harbarth, S. (2021). European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine). Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1128\/AAC.00086-15","article-title":"Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem","volume":"59","author":"Oteo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1128\/AAC.00533-15","article-title":"Effect of Resistance Mechanisms on the Inoculum Effect of Carbapenem in Klebsiella pneumoniae Isolates with Borderline Carbapenem Resistance","volume":"59","author":"Adler","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/CMR.05035-11","article-title":"Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: An evolving crisis of global dimensions","volume":"25","author":"Tzouvelekis","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s15010-017-1070-8","article-title":"Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: A case report and literature review","volume":"46","author":"Chibabhai","year":"2018","journal-title":"Infection"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00499-20","DOI":"10.1128\/AAC.00499-20","article-title":"Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018","volume":"64","author":"Lutgring","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00797-20","DOI":"10.1128\/AAC.00797-20","article-title":"Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","first-page":"253","article-title":"In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula","volume":"99","author":"Sonnevend","year":"2020","journal-title":"Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e00486-17","DOI":"10.1128\/AAC.00486-17","article-title":"In Vitro Discordance with In Vivo Activity: Humanized Exposures of Ceftazidime-Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi Metallo-beta-Lactamase-Producing Klebsiella pneumoniae in a Murine Lung Infection Model","volume":"61","author":"Monogue","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: A systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e00476-17","DOI":"10.1128\/AAC.00476-17","article-title":"In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/AAC.01870-15","article-title":"Correlation of beta-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program","volume":"60","author":"Bradford","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jgar.2021.08.010","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018","volume":"27","author":"Kiratisin","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e00775-17","DOI":"10.1128\/AAC.00775-17","article-title":"Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers","volume":"61","author":"Wenzler","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciaa003","article-title":"Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa","volume":"71","author":"Vena","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"Lok","year":"2018","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_57","first-page":"671","article-title":"Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins","volume":"27","author":"Wagenlehner","year":"2021","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: Systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study","volume":"17","author":"Salamanca","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Galani, I., Nafplioti, K., Adamou, P., Karaiskos, I., Giamarellou, H., and Souli, M. (2019). Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3801-1"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"ofz123","DOI":"10.1093\/ofid\/ofz123","article-title":"Plazomicin Is Active Against Metallo-beta-Lactamase-Producing Enterobacteriaceae","volume":"6","author":"Serio","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_63","first-page":"359","article-title":"Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: A call for international guidelines","volume":"22","author":"Roberts","year":"2016","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_64","first-page":"629","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: A position paper from the European Society of Clinical Microbiology and Infectious Diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcrc.2021.06.004","article-title":"Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Tang","year":"2021","journal-title":"J. Crit. Care"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4103\/0366-6999.205846","article-title":"Aerosolized Amikacin as Adjunctive Therapy of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Single-center Randomized Controlled Trial","volume":"130","author":"Liu","year":"2017","journal-title":"Chin. Med. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","article-title":"A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial","volume":"151","author":"Kollef","year":"2017","journal-title":"Chest"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1473-3099(19)30574-2","article-title":"Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): A double-blind, randomised, placebo-controlled, phase 3, superiority trial","volume":"20","author":"Niederman","year":"2020","journal-title":"Lancet. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1164\/rccm.201312-2161OC","article-title":"Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit","volume":"189","author":"Palmer","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13613-017-0301-6","article-title":"Nebulized antibiotics in mechanically ventilated patients: A challenge for translational research from technology to clinical care","volume":"7","author":"Ehrmann","year":"2017","journal-title":"Ann. Intensive Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e00079-17","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae","volume":"31","author":"Machuca","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Aitken, S.L., Bonomo, R.A., Mathers, A.J., van Duin, D., and Clancy, C.J. (2021). Infectious Diseases Society of America Guidance on the Treatment of AmpC beta-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., ciab1013.","DOI":"10.1093\/cid\/ciab1013"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1055\/s-0041-1733987","article-title":"How Antibiotics Stewardship Can Be Safely Implemented in Patients with Septic Shock?","volume":"42","author":"Timsit","year":"2021","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00134-015-4032-6","article-title":"Understanding PK\/PD","volume":"42","author":"Roberts","year":"2016","journal-title":"Intensive Care Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: Defining antibiotic levels in intensive care unit patients: Are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A Position Paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/QCO.0000000000000689","article-title":"Duration of antimicrobial therapy for Gram-negative infections","volume":"33","author":"Timsit","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/cid\/ciy1054","article-title":"Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: A Non-inferiority Randomized Controlled Trial","volume":"69","author":"Yahav","year":"2018","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/IDR.S294282","article-title":"Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study","volume":"14","author":"Zhou","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1001\/jama.2020.6348","article-title":"Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial","volume":"323","author":"Albrich","year":"2020","journal-title":"JAMA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","article-title":"Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial","volume":"375","author":"Bouadma","year":"2010","journal-title":"Lancet"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/2\/144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:06:25Z","timestamp":1760133985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/2\/144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":82,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["antibiotics11020144"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11020144","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]}}}